NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER
- Written by PR Newswire
- H002 is a precision therapeutic candidate for the treatment of NSCLC, with broad spectrum and high selectivity against multiple EGFR mutations including those with EGFR C797S mutation.
- RedCloud Bio has initiated H002 Phase I/IIa clinical studies in both China and US.
SHANGHAI, Aug. 29, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an...














